Medical treatment of Cushing disease: new targets, new hope.
This article provides an update on current medical therapies for the treatment of Cushing disease. This information will be of value in determining patients' suitability for certain medical treatments. An approach of combining drugs from the same or different classes could potentially increase the number of patients in whom Cushing can be controlled while minimizing adverse effects, although larger studies are needed. Successful clinical management of patients with Cushing disease remains a challenge.
Department of Medicine (Endocrinology), Oregon Health & Science University, Mail Code BTE 28, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA; Department of Neurological Surgery, Oregon Health & Science University, Mail Code BTE 28, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: fleseriu@ohsu.edu.
Maria
M
Fleseriu
D065607:Cytochrome P-450 Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006728:Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D065607:Cytochrome P-450 Enzyme Inhibitors; D006727:Hormone Antagonists; D006728:Hormones; D007093:Imidazoles; D011725:Pyridines; D015735:Mifepristone; D013004:Somatostatin; C553306:Osilodrostat; C517782:pasireotide
Combination therapies; Cushing disease; LCI699; Medical therapy; Mifepristone; Pasireotide